Sean Khozin, MD, MPH, has been named Chief Executive Officer of CancerLinQ LLC, and he will begin his new role overseeing the continued expansion and implementation of CancerLinQ, ASCO’s real-world oncology data platform designed to improve the quality of care for people with cancer and drive new research, on February 16.
On June 10, ASCO’s CancerLinQ® launched the SmartLinQ™ QOPI® Certification Pathway, an application that empowers oncology practices to automate quality measure tracking and reporting for participation in ASCO’s Quality Oncology Practice Initiative (QOPI) Certification Program, a three-year certification recognizing practices’ commitment to high-quality care for outpatient oncology practices.
On May 29, ASCO’s CancerLinQ® announced that it launched a new platform for CancerLinQ Discovery®, its de-identified real-world cancer data product for researchers across the cancer community.
Roswell Park Comprehensive Cancer Center of Buffalo, N.Y., has just signed an agreement to use the CancerLinQ® platform.
Two science-based organizations, CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology, and the American Heart Association, the leading voluntary health organization devoted to a world of longer, healthier lives, are teaming up to make oncology datasets from the CancerLinQ Discovery® database available to academic researchers, non-profits, health care providers and government agencies through a customized version of the American Heart Association’s Precision Medicine Platform.
ALEXANDRIA, Va. – The American Society of Clinical Oncology (ASCO) announced today the three recipients of its CancerLinQ Discovery® Research Support Grant. The awardees will undertake research projects using data from CancerLinQ Discovery®, an offering of ASCO’s CancerLinQ® initiative that provides de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve cancer care.
Chicago — In an effort to advance cancer data sharing and improve the quality and coordination of patient care, three of the nation’s leading health and technology organizations have established a core set of data elements and recommended technical specifications (the Minimal Common Oncology Data Elements, or “mCODE”) that are essential for capturing and reporting the characteristics, treatments, and outcomes of every cancer patient and should be contained in each patient’s electronic health record (EHR). The mCODE™ initiative, a collaboration between the American Society of Clinical Oncology, Inc. (ASCO®), its wholly owned nonprofit subsidiary CancerLinQ LLC, the MITRE Corporation, and the Alliance for Clinical Trials in Oncology Foundation (Alliance Foundation), released the initial set of common cancer data standards and specifications today at ASCO’s 2019 Annual Meeting in Chicago and published them online at mCODEinitiative.org.
ALEXANDRIA, Va.—CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), announced today that CureMD’s Electronic Health Record (EHR) system is the third to be certified by CancerLinQ® after meeting criteria for interoperability and data standardization. This collaboration will streamline access to CancerLinQ® and drive interoperability among EHR systems.
ALEXANDRIA, Va.—CancerLinQ LLC and the International Association for the Study of Lung Cancer (IASLC) have announced a collaboration to expand the specialized expertise informing CancerLinQ®, a health information technology platform, developed by oncologists for oncologists, to enhance and improve the understanding and treatment of cancer. The IASLC will contribute thought leadership and subject matter expertise to CancerLinQ including aspects of clinical practice related to the diagnosis and management of lung cancer, the identification and development of clinical quality measures for thoracic oncology, and other relevant content.
ALEXANDRIA, Va.— The number of electronic health record (EHR) systems joining with CancerLinQ to facilitate information sharing continues to grow. CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), announced today that Varian’s ARIA® Oncology Information System (OIS) is the next Electronic Health Record (EHR) System to be certified by CancerLinQ® after meeting criteria for interoperability and data standardization. This collaboration aims to dismantle barriers to information sharing and streamline access to CancerLinQ for oncology practices using Varian ARIA® OIS.
ALEXANDRIA, Va.—The American Society of Clinical Oncology (ASCO) announced today that it is seeking applications for research grants for projects that use data from CancerLinQ Discovery®, an offering of ASCO's CancerLinQ® initiative, as a source. CancerLinQ Discovery® provides curated sets of de-identified data from cancer patients to academic researchers, government agencies, and others in the oncology community to generate practical knowledge that will improve cancer care.
Alexandria, Va. — CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Stanford Health Care has signed an agreement to participate in the CancerLinQ® platform. Stanford Health Care includes Stanford Cancer Institute which is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
ALEXANDRIA, Va. – CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that oversees the development and operation of CancerLinQ®, a health information technology platform working to improve quality and value of care for all patients by connecting cancer care team members, researchers, and sponsors with real-world cancer data. In addition, CancerLinQ and Integra Connect have entered into an agreement to collaborate on products and services geared toward improving the quality of cancer care and the access of the CancerLinQ® platform to oncology practices.
Alexandria, Va. — CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), has brought on technology collaborators Concerto HealthAI and Tempus to accelerate its joint research effort with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) aimed at understanding the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors. Concerto HealthAI and Tempus have begun to assist in the analysis of a de-identified data set that CancerLinQ has provided to the FDA, representing more than 10,000 patients who have been treated with immune checkpoint inhibitors for both approved and unapproved indications.
ALEXANDRIA, Va. — Cory Wiegert has been named Chief Executive Officer (CEO) of CancerLinQ LLC, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO). Mr. Wiegert, a proven expert in building and successfully launching innovative technology solutions, will begin his new role on August 13, 2018, overseeing the continued expansion and implementation of the CancerLinQ® platform.